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Events that occur in the early fetal environment have been linked to long-term health and lifespan consequences in the adult.
Intrauterine growth restriction (IUGR), which may occur as a result of nutrient insufficiency, exposure to hormones, or disruptions
in placental structure or function, may induce the fetus to alter its developmental program in order to adapt to the new conditions.
IUGR may result in a decrease in the expression of genes that are responsible for nephrogenesis as nutrients are rerouted to the
development of more essential organs. Fetal survival under these conditions often results in low birth weight and a deficit in
nephron endowment, which are associated with hypertension in adults. Interestingly, male IUGR offspring appear to be more
severely affected than females, suggesting that sex hormones may be involved. The processes of fetal programming of hypertension
are complex, and we are only beginning to understand the underlying mechanisms.
1. Introduction
Hypertension is a powerful independent risk factor for the
development of well-known cardiovascular and cerebrovas-
cular morbidities that include myocardial infarction, stroke,
atherosclerosis, and death. It is a prevalent disorder that af-
fects close to a quarter of the adult population worldwide [1].
Although often considered as a late-onset chronic disorder,
hypertension is now recognized to afflict the young popula-
tion, from neonates to adolescents. While the diagnosis of hy-
pertension in adults is based on empirically determined cut-
off values for both systolic and diastolic blood pressure (BP),
the diagnosis of pediatric hypertension is not as straightfor-
ward since it is based on normative data [2]. Hypertension
in the young is defined as the average systolic or diastolic BP
that is ≥95th percentile according to age, sex, and height on
three or more occasions [2]. There are no target BP values
that indicate high blood pressure in children, since BP chan-
ges with age; neonates have low BP that gradually increases
with age [3]. The prevalence of pediatric hypertension is es-
timated at 1-2% [4] and seems to have steadily increased
during the past decade, which correlates with the increase in
the prevalence of obesity [5].
A striking concept on the etiology of hypertension that
has emerged during the last few decades is what is known as
fetal imprinting, or developmental programming. This con-
cept refers to the observation that adverse environmental in-
sults early in life, particularly during critical periods of devel-
opment in utero and the early postnatal period, can result in
silent yet long-term morphological and physiological alter-
ations that eventually translate into disease in adulthood [6].
The correlation between adverse intrauterine conditions and
subsequent cardiovascular disorders was first proposed by
Barker who reported a link between the mortality rate of cor-
onary artery disease and birth weight [7, 8]. Barker hypothe-
sized that adaptive responses to an environmental insult dur-
ing early life may persist and become harmful during adult-
hood when the insult is no longer present. A compelling
body of work from various groups around the world has
corroborated these findings and has expanded the concept
to include other conditions such as type 2 diabetes, obesity,
and chronic kidney disease [6].
The biological and molecular mechanisms involved
in fetal imprinting are multiple, though not completely
understood, and include low birth weight (“small baby
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syndrome”), glucocorticoid excess, uteroplacental deficiency,
sexual dimorphism, and epigenetics.
2. Low Birth Weight and Hypertension
Low birth weight (LBW), defined as birth weight of <2500 g
by the World Health Organization, may arise from intrauter-
ine growth restriction (IUGR, or birth weight that is <10th
percentile for gestational age) or prematurity [6], with the
former exerting a stronger predisposition for disease to de-
velop and manifest later in life [9]. Several animal models
have demonstrated the inverse relationship between LBW
and hypertension [10, 11], which was attributable to a deficit
in nephron number. Moreover, humans with LBW have sig-
nificantly higher BPs, even after correction for various mod-
ifiers such as sex, cigarette smoking, weight, and use of oral
contraceptives [6].
Two distinct mechanisms have been proposed to explain
why LBW antedates the development of adult hypertension.
Numerous studies indicate that birth weight is a strong
predictor of nephron number and mean glomerular volume
in several racial groups [12, 13]. In humans, nephrons are
formed between 28–34 weeks of gestation, after which the in-
dividual has achieved a finite nephron number endowment
for life (an average of 750,000 per kidney), that is, no ad-
ditional nephrons are formed thereafter [14, 15]. Postnatally,
an increase in tubular length and glomerular size, which
varies inversely with nephron number, is achieved [16].
IUGR curtails the formation of adequate nephron number in
the growing fetus, which compromises the available filtration
surface area and leads to hypertension in adults [17]. Neph-
ron-deficient rats have been shown to exhibit sodium-de-
pendent hypertension and albuminuria [18], while post-
mortem examination of kidneys from hypertensive Cauca-
sians reveals significantly fewer glomeruli per kidney and
greater glomerular volume [19]. Infants who suffered from
IUGR have 30–35% reduced nephron number endowment
[20]. Endothelial dysfunction in individuals with LBW
is another mechanism that may explain the development
of hypertension later in life [21]. The perturbation of
endothelial function may be due to impaired angiogenesis
during fetal development or an apparent reduction in the
production or function of nitric oxide [21, 22].
Other factors such as increases in inflammatory cytok-
ines, the expression of metabolic genes, and changes in blood
vessel formation—all of which can contribute to high blood
pressure in adults—have been detected in fetuses with
IUGR [23–26]. Additionally, the expression and activity of
ion transporters such as Na+K+-ATPase [27] and sodium-
hydrogen exchanger 3 [28] are increased with IUGR, which




In 3–10% of pregnancies in the Western world, the flow of
blood from mother to fetus is inadequate, resulting in utero-
placental insufficiency (UPI) [29]. UPI subjects the fetus to
stressors which are not normally encountered during devel-
opment, such as hypoxia, altered hormone concentrations,
and decreased nutrition. These unfavorable environmental
factors result in the development of conditions such as IUGR
[30], which typically begins midway through pregnancy and
continues through the end of gestation [31]. In the presence
of UPI, the fetus must deviate from its normal developmental
trajectory during this critical period of growth in order to
ensure the formation of vital organs and survival in adverse
conditions. Though these changes may be beneficial during
early life, they often lead to deleterious conditions such as
hypertension in adulthood [32–34].
The trafficking of nutrients, hormones, and other factors
essential for the development of the kidneys and vasculature
is disrupted in IUGR placentas and thus may play a role in
the development of hypertension. Studies have shown that
downregulation of amino acid transporters [35–40], lowered
fetomaternal blood flow [35, 41], and structural abnormali-
ties are present in IUGR placentas [42–44]. Since the placenta
is the medium through which the fetus receives all factors
necessary for growth, disruptions in placental structure or
function may alter the development of fetal vasculature, or-
gans, or signaling pathways in ways that predispose the fetus
to later development of hypertension.
As previously mentioned, the process of nephrogenesis in
humans is completed by weeks 34–36 of gestation [14, 15].
IUGR that occurs prior to the generation of the full neph-
ron complement may result in reduced renal mass [45–47],
decreased nephron and glomerular endowment, and in-
creased protein excretion [46, 48–50].
IUGR may result in a decrease in the expression of genes
involved in nephrogenesis [51, 52], as well as a rerouting of
nutrients from the kidney to more essential organs such as
the brain, adrenal glands, and heart in order to enable sur-
vival of the fetus [53, 54]. While such changes allow for fetal
survival during early development, they may increase the risk
of susceptibility to renal injury or malfunction during adult-
hood [55–57] as a result of diminished nephron number and
renal size [17, 58–60].
Studies of IUGR in animal models have demonstrated
how highly sensitive the developing kidney is to perturba-
tions of the intrauterine environment, especially during the
early stages of nephrogenesis. Maternal dietary manipulation
is commonly employed to induce IUGR during fetal devel-
opment [46, 47] which results in reduced nephrogenesis,
suppression of the renin-angiotensin system (RAS), and hy-
pertension in the adult animal. Significantly, the timing of
the induction of fetal IUGR is directly related to the out-
come in the adult. The greatest impact on adult blood pres-
sure is observed when IUGR coincides with the period of
nephrogenesis. This indicates the importance of kidney mor-
phology in the programming of blood pressure in the adult
[49].
4. Sexual Dimorphism and Hypertension
Sex hormones may have a regulatory effect on the develop-
ment of hypertension in adult IUGR offspring. While both
male and female IUGR offspring are hypertensive early in
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life, only males remain hypertensive into adulthood. Many
studies have shown that estrogen may play a protective role
against the development of hypertension in female IUGR off-
spring [61]. This is supported by the fact that postmen-
opausal women are at an increased risk for hypertension. In
animal models, ovariectomized female IUGR offspring be-
come hypertensive like their male counterparts, whereas
non-IUGR control females do not become hypertensive [61].
Estradiol (E2) replacement lowered blood pressure in both
IUGR and control rats. It was also found that E2 levels at
16 weeks of age were not significantly different between
IUGR and control offspring [61]. This seems to suggest that
the protective role of estrogen does not play a direct role in
regulating blood pressure, but may do so by regulating an-
other mechanism such as the RAS.
Testosterone seems to play a role in the stimulation of the
RAS as well, which may explain the increased blood pressure
in male IUGR offspring [61]. Testosterone levels were signif-
icantly higher in intact male IUGR offspring when compared
to control offspring [62]. This may inappropriately stimulate
the RAS and increase blood pressure [63]. Hypertension was
abolished in male IUGR offspring that underwent castration,
and treatment with testosterone raised their blood pressure
back to hypertensive levels [62, 63]. Castration of the male
control rats did not have a significant effect on blood pressure
[62, 63]. The ACE inhibitor Enalapril abolished hypertension
in both male and female IUGR offspring, indicating that
the RAS is involved in the regulation of hypertension. Taken
together, it seems that testosterone acts as a stimulant of the
RAS, which increases blood pressure, while estrogen acts as
an inhibitor, lowering blood pressure in females.
Maternal diet has been shown to have a large impact on
the fetal programming of hypertension, although this too has
a clear sexual dimorphism. Males appear to be much more
sensitive to insult in utero than their female counterparts
[64]. Studies show that in cases of moderate fetal insult due
to a protein-restricted or global-restricted diet, male IUGR
offspring developed and remained hypertensive while their
female counterparts seemed to be protected [16, 64]. Female
IUGR offspring only responded with an increase in blood
pressure to severe insult during development [64]. There
could be two reasons to explain this dichotomy. One may be
the influence of the sex hormones testosterone and estrogen
on the RAS. Increased testosterone levels in male IUGR
offspring may explain their increased sensitivity to hyperten-
sion, while the effect of estrogen explains the protected status
of female offspring. Another explanation may be “catch-up
growth” of IUGR offspring. While both males and females
exhibit low birth weight as a result of reduced uterine
perfusion, male IUGR offspring undergo catch-up growth
[16, 64, 65]. This causes male IUGR offspring to have an
above-average body mass as adults, which may be a factor
in the development of hypertension [64].
5. Glucocorticoids and Hypertension
Glucocorticoids are potent regulators of fetal growth
and have been associated with long-term effects on the
development and morphogenesis of the growing fetus.
Corticosteroid therapy for neonates at risk of preterm
delivery and respiratory distress syndrome (RDS) has been
the standard of treatment since the landmark paper by
Liggins and Howie in 1972 [66]. Some pathophysiological
effects of glucocorticoid excess are hypertension, impaired
sugar metabolism, and abnormalities in neuroendocrine
responses [67–69].
There are two ways by which an elevation of glucocor-
ticoids may occur in utero. First, suboptimal placental or
maternal nutrient supply results in increased glucocorticoid
levels, which restrict fetal growth and program permanent
changes in the cardiovascular, endocrine, and metabolic
systems [70]. Second, exposure to exogenous glucocorticoids
may occur, such as in neonates treated with glucocorticoids
for respiratory-related disorders. Antenatal administration
of exogenous or increased endogenous glucocorticoids
results in LBW [71] and alters the maturation of a variety
of organs.
Glucocorticoids are lipophilic molecules that cross the
placenta. Fetal glucocorticoid levels are much lower than
maternal levels. In order to maintain this difference, the
placenta is saturated with the enzyme 11-β-hydroxysteroid
dehydrogenase type 2 (11-β-HSD2), which rapidly inacti-
vates glucocorticoids to their inert 11-keto forms (cortisone,
11-dehydrocorticosterone) [72]. This process reduces fetal
exposure to maternally active glucocorticoids. If the fetus
is genetically deficient in the 11-β-HSD2, it may exhibit
LBW and metabolic disorders. For example, heterozygous
individuals carrying the deleterious 11-β-HSD2 gene allele
had extremely low birth weights with respect to siblings who
were homozygous for the wild-type gene and born with
normal weights [69]. Studies in rats show that a decrease in
11-β-HSD2 activity results in LBW and hypertension in the
adult animal [73].
The exact mechanism of action for glucocorticoids and
the pathogenesis of hypertension have been characterized
in several physiological systems. Increased production of
reactive oxygen species, the activation of the RAS, and
impairment of nephron development are all associated
with increased sodium retention in neonates exposed to
glucocorticoids [68, 74]. Research has found a critical period
in early fetal development during which glucocorticoid
treatment will lead to hypertension; soon after this time
period, most of the organs will have developed, and thus
glucocorticoid exposure will not have as profound an effect
on their morphogenesis. In one study, offspring of pregnant
ewes exposed to glucocorticoids developed impaired renal
function and glomerular filtration rate. In two-month-old
female offspring of these glucocorticoid-treated ewes, the
α-, β-, γ-subunits of Na+/K+-ATPase were upregulated in
the kidney, indicating a potential mechanism of action for
development of hypertension [75].
Genetic predisposition can also play a role in the
alteration of the glucocorticoid receptor function. The 23 K
variant of the R23K SNP of the glucocorticoid receptor
has been shown to protect against neonatal development of
insulin resistance and growth failure. This has been shown by
a study that evaluated the relative sensitivity of an individual
to cortisol in a cohort of 249 19-year-old subjects who were
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born at less than 32 weeks gestational age. The investigators
determined that genomic polymorphisms may play a role in
the sensitivity of neonates to glucocorticoid exposure and
may have permanent effects as a result of fetal programming
[76]. Mutations in the 11-β-HSD2 have been linked with very
low birth weights in patients with apparent mineralocorti-
coid excess, leading to juvenile hypertension [74].
6. Fetal Programming and Epigenetics
Epigenetic modification of DNA by methylation occurs
primarily at CpG dinucleotides and serves as a mechanism
of gene silencing. Studies using rodent models of maternal
protein restriction during gestation have shown that reduced
methylation of genes occurs in the offspring [77, 78].
Using a similar system, Bogdarina et al. [79] demonstrated
decreased methylation at the proximal promoter region
of the angiotensin receptor, type b gene (Agtr1b), which
correlated with increased expression of the receptor in the
adrenal gland of the offspring. Agtr1b, however, is not found
in humans. Nevertheless, these results suggest a link between
IUGR and epigenetic modification of genes related to the
regulation of blood pressure [78]. More recently, Bogdarina
et al. [80] found that treating pregnant rats with metyrapone,
an 11 β-hydroxylase inhibitor, during the first two weeks
of pregnancy normalized the methylation of the promoter
region of the Agtr1b, reduced the expression of the Agtr1b
receptor, and prevented the development of hypertension in
the offspring. While few of these types of studies have been
conducted, the results are exciting and further investigation
is certainly warranted.
7. Conclusion
Twenty years ago, Hales and Barker proposed that events
that occur in the early fetal environment may be linked to
long-term health and lifespan consequences in the adult [81].
Numerous subsequent studies have largely supported their
hypothesis and serve to illustrate the overarching complexity
of the maternal-fetal-environmental interaction. While this
review was necessarily limited in scope to only the effect of
IUGR on hypertension, the reader should be made aware that
this is but one component of a constellation of metabolic
disorders that may arise as a result of a severe perturbation
of the fetal environment.
The focus of most of the studies reviewed has been the
impact of IUGR on the adult animal. We would suggest that
additional studies be devoted to elucidating the mechanisms
employed by the fetus in order to rapidly adapt to its altered
environment. It is by better understanding these mechanisms
that we may be able to develop interventional strategies that
may prevent the onset of disease in the adult.
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